
Bausch Health Companies Inc. (TSE:BHC – Free Report) – Equities research analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Bausch Health Companies in a research note issued to investors on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the company will earn $1.67 per share for the quarter, up from their prior estimate of $1.63. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q1 2027 earnings at $1.21 EPS, Q2 2027 earnings at $1.36 EPS, Q4 2027 earnings at $1.49 EPS, FY2027 earnings at $5.56 EPS, Q1 2028 earnings at $0.97 EPS, Q2 2028 earnings at $1.28 EPS and FY2028 earnings at $4.32 EPS.
Bausch Health Companies (TSE:BHC – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported C$2.52 EPS for the quarter. The firm had revenue of C$4.19 billion during the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%.
Bausch Health Companies Price Performance
Bausch Health Companies announced that its board has authorized a share buyback program on Wednesday, October 28th that allows the company to buy back C$70 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.9% of its shares through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.
Insider Transactions at Bausch Health Companies
In other Bausch Health Companies news, insider Mirza Dautbegovic sold 20,000 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the completion of the sale, the insider directly owned 224,745 shares in the company, valued at approximately C$2,512,649.10. The trade was a 8.17% decrease in their position. Corporate insiders own 11.28% of the company’s stock.
Recent Bausch Health Companies Headlines
Here are a few of the latest headlines about BHC:
- Positive Sentiment: Zacks raised its FY2026 EPS estimate to $7.11 from $5.95 and its FY2027 estimate to $5.56 from $5.40. It also lifted estimates for several quarters in late 2026 and 2027, and nudged FY2028 EPS to $4.32 from $4.28. These upward revisions suggest improved expectations for much of the forecast period. Bausch Health Companies analyst estimates
- Negative Sentiment: Zacks lowered its Q3 2028 EPS estimate to $1.02 from $1.14, tempering the more favorable revisions elsewhere. The overall outlook remains mixed, and the estimate changes alone do not establish the reason for the share decline. Bausch Health Companies analyst estimates
Bausch Health Companies Company Profile
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Featured Articles
- Five stocks we like better than Bausch Health Companies
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
